http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.
Jessen, F. (First author)DZNE* ; Wolfsgruber, S.DZNE* ; Kleineindam, L. ; Spottke, A.DZNE* ; Altenstein, S.DZNE* ; Bartels, C.Extern* ; Berger, M. ; Brosseron, F.DZNE* ; Daamen, M.DZNE* ; Dichgans, M.DZNE* ; Dobisch, L.DZNE* ; Ewers, M.Extern* ; Fenski, F. ; Fließbach, K.Extern* ; Freiesleben, S. D.Extern* ; Glanz, W.DZNE* ; Görß, D.DZNE* ; Gürsel, S. ; Janowitz, D.Extern* ; Kilimann, I.DZNE* ; Kobeleva, X.Extern* ; Lohse, A.Extern* ; Maier, F. ; Metzger, C.DZNE* ; Munk, M.Extern* ; Preis, L.Extern* ; Sanzenbacher, C.Extern* ; Spruth, E. J.Extern* ; Rauchmann, B. S.Extern* ; Vukovich, R. C.Extern* ; Yakupov, R.DZNE* ; Weyrauch, A.-S.DZNE* ; Ziegler, G.DZNE* ; Schmid, M.DZNE* ; Laske, C.DZNE* ; Perneczky, R.DZNE* ; Schneider, A.DZNE* ; Wiltfang, J.DZNE* ; Teipel, S.DZNE* ; Bürger, K.DZNE* ; Priller, J.DZNE* ; Peters, O.DZNE* ; Ramirez, A.DZNE* ; Boecker, H.DZNE* ; Heneka, M. T.DZNE* ; Wagner, M.DZNE* ; Düzel, E. (Last author)DZNE*
2023
Wiley
Hoboken, NJ
This record in other databases:
Please use a persistent id in citations: doi:10.1002/alz.12674
Abstract: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum.Cross-sectional and longitudinal data from the multicenter, memory clinic-based DELCODE study.The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD-A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO-A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group.Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.
Keyword(s): Humans (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Amyloid beta-Peptides (MeSH) ; Cross-Sectional Studies (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Cognition (MeSH) ; Biomarkers (MeSH) ; tau Proteins (MeSH) ; Alzheimer's disease ; amyloid beta 42 ; apolipoprotein E ; cerebrospinal fluid ; longitudinal ; magnetic resonance imaging ; mild cognitive impairment ; positron emission tomography ; subjective cognitive decline ; tau
Note: (CC BY-NC-ND)
Contributing Institute(s):
- Clinical Alzheimer’s Disease Research (AG Jessen)
- Neuropsychology (AG Wagner)
- Patient Studies (AG Klockgether)
- Interdisciplinary Dementia Research (AG Endres)
- Interventional Trials and Biomarkers in Neurodegenerative Diseases (Biomarker)
- Positron Emissions Tomography (PET) (AG Boecker)
- Clinical Research (Munich) (Clinical Research (Munich))
- Linking imaging projects iNET (AG Speck)
- Cooperation Unit for Applied Prevention Research (KAP) (KAP)
- Clinical Neurophysiology and Memory (AG Düzel)
- Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
- Mathematics, statistics and informatics methods for support of population studies and clinical research (AG Schmid Bonn)
- Core ICRU (Core ICRU)
- Translational Dementia Research (Bonn) (AG Schneider)
- Translational Neuropsychiatry (AG Priller)
- Patient Studies Bonn (Patient Studies Bonn)
- Delcode (Delcode)
Research Program(s):
- 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
Experiment(s):
- Longitudinal Cognitive Impairment and Dementia Study
Appears in the scientific report
2023
Database coverage:
;

;

; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection